Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
IOPAMIDOL-200 vs IOPAMIDOL-200 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
None Documented
None Documented
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent